The Workbench · Craft
Australia's TGA pathway leans on someone else's review
This blog has already covered how Japan's device pathway forks on whether a certification standard exists, and how Health Canada splits company-level and device-level authorization into two separate instruments. Australia's Therapeutic Goods Administration runs a third model again: rather than a class-based fork or a two-tier licence, the TGA lets an accepted overseas regulator's own finished review stand in for part of its own. A sponsor that reads that as a foreign clearance travelling whole into the Australian Register of Therapeutic Goods has misread how much of the file the reliance actually reaches.
Abridgement, not recognition
The TGA's own guidance on using assessments from comparable overseas regulators lets a sponsor submit evidence from a named list of foreign bodies — European notified bodies, the US FDA's 510(k), De Novo, or PMA decisions, Health Canada's medical device licence, UK-approved bodies, and Singapore's Health Sciences Authority among them — as the basis for abridging the assessment the TGA would otherwise run in full on a conformity assessment or ARTG inclusion application. Abridging is the operative word: the TGA reduces how much of its own review it has to duplicate against evidence a comparable regulator has already produced, it does not adopt that regulator's decision as its own. The reliance runs one direction, on named bodies the TGA itself has vetted, not on any overseas approval a sponsor happens to hold.
What still runs through Australia alone
An accepted overseas assessment narrows the conformity-assessment work, not the whole application. Schedule 1 of the Therapeutic Goods (Medical Devices) Regulations 2002 sets Australia's own Essential Principles — its equivalent of the general safety and performance requirements this blog has already traced through MDR's own essential-performance test — and a sponsor still has to demonstrate alignment against that Australian text, not merely attach the overseas certificate and move on. Labelling has its own Australia-specific content requirements independent of what a CE mark or an FDA clearance letter required elsewhere. And inclusion in the ARTG is the TGA's own database action: nothing about an overseas approval populates it automatically, and no device can be supplied in Australia before that entry exists, whatever conformity assessment work the reliance pathway abridged.
An Australian sponsor still has to hold the file
The abridged pathway also doesn't relieve a manufacturer of needing its own Australian sponsor — a locally based entity that takes on the regulatory responsibilities the Act assigns, the same structural role this blog has already covered for an EU authorised representative's mandate. Different statute, same underlying logic: a market that lets a device answer to a foreign manufacturer's decisions still insists on a local party who can be reached, and reliance on someone else's conformity assessment doesn't touch that requirement at all. A submission that treats the Australian sponsor as a formality to fill in after the reliance evidence is assembled has the order of operations backwards.
The reliance is live, not a one-time credit
An accepted overseas decision keeps doing work for the Australian file only as long as it stays valid on its own terms. A suspended CE certificate, a withdrawn 510(k) clearance, or a lapsed Health Canada licence doesn't leave the Australian approval untouched just because the abridged review already happened once; the TGA's own guidance treats the underlying overseas status as something a sponsor has to keep current, not a credit banked at time of filing. This blog has already covered how a US FEI can keep answering to a registration that's since gone stale — the Australian reliance pathway runs the opposite risk, where the Australian approval is the one left exposed if the foreign anchor it borrowed from stops holding.
Where this meets the file
A multi-jurisdiction filing tracker needs a field for which named comparable regulator's evidence an Australian submission relies on, the specific certificate or clearance number cited, and a standing flag to recheck that status rather than a note filed once and forgotten. A reliance-pathway worksheet built around that structure, alongside the Japan and Health Canada logic this blog has already covered, is previewed in the launch catalog. If your program has run a TGA reliance submission and found gaps this one misses, the shelf takes that correction directly.
The Regulatory Toolkit launches soon — a free shelf of source-mapped templates, checklists and browser-only tools for regulatory teams. Get one email when it opens, or contribute a template.